Application of omental interposition to reduce pancreatic fistula and related complications in pancreaticoduodenectomy: A propensity score-matched study

Table 1 Comparisons of patients’ characteristics between the two groups

	Before PSM			After PSM
	Omental interposition group (127)	Non-omental interposition group (69)	P value	Omental interposition group (69)	Non-omental interposition group (69)	P value
Male/female	79/48	44/25	0.919	46/23	44/25	0.721
Age (yr)	64.8 ± 10.5	62.1 ± 9.9	0.083	64.2 ± 9.5	62.1 ± 9.9	0.210
BMI (mean ± SD, kg/m2)	21.9 ± 3.0	22.0 ± 2.8	0.844	21.9 ± 3.2	22.0 ± 2.9	0.933
ASA score, n (%)			0.126			0.168
I	65 (51.2)	42 (60.9)		34 (49.3)	42 (60.9)
II	60 (47.2)	24 (34.8)		34 (49.3)	24 (34.8)
III	2 (1.6)	3 (4.3)		1 (1.4)	3 (4.3)
Serum ALB [n (%), g/L]			0.152			1.00
< 35	13 (10.2)	12 (17.4)		12 (17.4)	12 (17.4)
≥ 35	114 (89.8)	57 (82.6)		57 (82.6)	57 (82.6)
Serum bilirubin (μmol/L)	96.5 (17.9-107.0)	20.5 (9.6-148.5)	0.015	29.8 (12.4-153.7)	20.5 (9.6-148.5)	0.753
Main pancreatic duct size [n (%), mm]			0.080			0.173
< 3	57 (44.9)	40 (58.0)		32 (46.4)	40 (58.0)
≥ 3	70 (55.1)	29 (42.0)		37 (53.6)	29 (42.0)
Operation method, n (%)			0.005			0.708
LPD	69 (54.3)	19 (27.5)		21 (30.4)	19 (27.5)
OPD	58 (45.7)	50 (72.5)		48 (69.6)	50 (72.5)
Pathology, n (%)			0.009			0.151
PDAC	53 (41.7)	25 (36.2)		36 (52.2)	25 (36.2)
Bile duct cancer	10 (7.9)	13 (18.8)		4 (5.8)	13 (18.8)
Ampulla of Vater cancer	18 (14.2)	15 (21.7)		10 (14.5)	15 (21.7)
Duodenal cancer	11 (8.7)	2 (2.9)		2 (2.9)	2 (2.9)
Other carcinoma	19 (15.0)	2 (2.9)		3 (4.3)	2 (2.9)
Benign tumor	16 (12.6)	12 (17.4)		14 (20.3)	12 (17.4)

ALB: Albumin; ASA: American Society of Anesthesiologist score; BMI: Body mass index LPD: Laparoscopic pancreaticoduodenectomy; OPD: Open pancreaticoduodenectomy.